209 related articles for article (PubMed ID: 35038671)
1.
Kara F; Joers JM; Deelchand DK; Park YW; Przybelski SA; Lesnick TG; Senjem ML; Zeydan B; Knopman DS; Lowe VJ; Vemuri P; Mielke MM; Machulda MM; Jack CR; Petersen RC; Öz G; Kantarci K
Neurobiol Aging; 2022 Apr; 112():16-26. PubMed ID: 35038671
[TBL] [Abstract][Full Text] [Related]
2. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
3. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's pathology targets distinct memory networks in the ageing brain.
Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
[TBL] [Abstract][Full Text] [Related]
5. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.
Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y
Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815
[TBL] [Abstract][Full Text] [Related]
6. Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study.
Zeydan B; Deelchand DK; Tosakulwong N; Lesnick TG; Kantarci OH; Machulda MM; Knopman DS; Lowe VJ; Jack CR; Petersen RC; Öz G; Kantarci K
J Neuroimaging; 2017 Nov; 27(6):630-636. PubMed ID: 28661060
[TBL] [Abstract][Full Text] [Related]
7. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
[TBL] [Abstract][Full Text] [Related]
8. Investigating neural dysfunction with abnormal protein deposition in Alzheimer's disease through magnetic resonance spectroscopic imaging, plasma biomarkers, and positron emission tomography.
Matsuoka K; Hirata K; Kokubo N; Maeda T; Tagai K; Endo H; Takahata K; Shinotoh H; Ono M; Seki C; Tatebe H; Kawamura K; Zhang MR; Shimada H; Tokuda T; Higuchi M; Takado Y
Neuroimage Clin; 2024; 41():103560. PubMed ID: 38147791
[TBL] [Abstract][Full Text] [Related]
9. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
11. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
[TBL] [Abstract][Full Text] [Related]
12. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
13. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer's disease spectrum patients.
Shigemoto Y; Sone D; Maikusa N; Okamura N; Furumoto S; Kudo Y; Ogawa M; Takano H; Yokoi Y; Sakata M; Tsukamoto T; Kato K; Sato N; Matsuda H
Brain Behav; 2018 Dec; 8(12):e01145. PubMed ID: 30358161
[TBL] [Abstract][Full Text] [Related]
14. Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.
Murray ME; Przybelski SA; Lesnick TG; Liesinger AM; Spychalla A; Zhang B; Gunter JL; Parisi JE; Boeve BF; Knopman DS; Petersen RC; Jack CR; Dickson DW; Kantarci K
J Neurosci; 2014 Dec; 34(49):16247-55. PubMed ID: 25471565
[TBL] [Abstract][Full Text] [Related]
15. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
16. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of sleep duration and physical activity on cognitive performance are influenced by β-amyloid and brain volume but not tau burden among cognitively unimpaired older adults.
Aslanyan V; Ortega N; Fenton L; Harrison TM; Raman R; Mack WJ; Pa J
Neuroimage Clin; 2023; 39():103460. PubMed ID: 37379733
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
19. Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
Chen X; Toueg TN; Harrison TM; Baker SL; Jagust WJ
Ann Neurol; 2024 Feb; 95(2):249-259. PubMed ID: 37789559
[TBL] [Abstract][Full Text] [Related]
20. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
